Back

Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention

29 August 2026 (15:00 - 15:10)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ademola Ajibade

University of Iowa Hospitals and Clinics, Iowa City (United States of America)

5 More presentations in this session

Presentation thumbnail
The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK
Professor K. Ray (London, GB)
Abstract
Presentation thumbnail
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
Assistant Professor M. Leening (Rotterdam, NL)
Abstract
Presentation thumbnail
Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study
Doctor M. Yang (Chengdu, CN)
Abstract
Presentation thumbnail
Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV
Professor J. Nicolau (Sao Paulo, BR)
Abstract
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics

The Event

Event poster

ESC Congress 2026

29 August 2026 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
3 September 2019
thumbnail
Congress Presentation
Statins for primary prevention among elderly men and women.
27 August 2021
thumbnail
Congress Presentation
LDL-C reduction and residual cardiovascular risk in heterozygous familial hypercholesterolemia: a matched cohort study in South Wales
1 September 2025
thumbnail
Congress Presentation
Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources